Wonderful news, Nirupma.
I hope his side effects improve.
Thank you for the update.
J
http://www.cancer.gov/cancertopics/pdq/treatment/childrhabdomyosarcoma/healthpro
fessional

   * The alveolar subtype is more prevalent among patients with less
favorable clinical features (e.g., younger than 1 year or older than 10
years, extremity primaries, and metastatic disease), and is generally
associated with a worse outcome. In the IRS-I and IRS-II studies, the
alveolar subtype was associated with a less favorable outcome even in
patients whose primary site was completely resected (Clinical group I).[24]
Statistically-significant differences in survival for histopathologic
subtype were not, however, noted when all patients with rhabdomyosarcoma
were analyzed,[30] nor were differences noted by histologic subtype in a
large group of German children with rhabdomyosarcoma.[23] In the IRS-III
study, outcome for patients with Clinical group I alveolar subtype tumors
was similar to those of other patients with Clinical group I tumors, but
the patients with alveolar subtype received more intensive therapy.[4]

   * Patients with undifferentiated sarcoma have been eligible for
participation in rhabdomyosarcoma trials coordinated by the Intergroup
Rhabdomyosarcoma Study Group (IRSG) and the Children’s Oncology Group
(COG). The rationale for this inclusion was the observation that patients
with undifferentiated sarcoma have similar sites of disease and outcome to
those with alveolar rhabdomyosarcoma (ARMS). In therapeutic trials for
adults with soft tissue sarcoma, patients with undifferentiated sarcoma are
included with all other histologies and treated in a similar manner.
Contemporary treatment for adult soft tissue sarcoma utilizes ifosfamide
and doxorubicin, sometimes with the addition of other chemotherapy agents,
surgery, and radiation therapy. There are no data to compare these two
approaches.

Because treatment and prognosis depend, in part, on the histology and
molecular genetics of the tumor, it is necessary that the tumor tissue be
reviewed by pathologists with experience in the evaluation and diagnosis of
tumors in children. Additionally, the diversity of primary sites, the
distinctive surgical and radiation therapy treatments for each primary
site, and the subsequent site-specific rehabilitation underscore the
importance of treating children with rhabdomyosarcoma in medical centers
with appropriate experience in all therapeutic modalities.

X-No-Archive

That is great news thanks for sharing.
Alex

Thanks for sharing....alex

I am so glad to read this.  Please tell him that he has a small fan club in
North Carolina, and that we're all rooting for him.  I hope that things
continue to improve for him.

Pam S.

Dear friends,

Thank you all. This place really gives us courage to move ahead despite
everything.

God Bless,
Nirupma Kapoor